Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177718 · ClinicalTrials.gov registry record · Phase 4
Natalizumab and Chronic Inflammation
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT05177718: Clinical Trial Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT05177718 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05177718, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
Primary Outcome
To measure changes in k-trans between baseline (pre-treatment) and month-3 and month-12 post-treatment scan
Interventions
- DRUG Natalizumab 300 MG in 15 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 4 |
Why NCT05177718 stopped before completion
NCT05177718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Natalizumab 300 MG in 15 ML Injection is the first listed.
NCT05177718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05177718 about?
NCT05177718 is a clinical study titled "Natalizumab and Chronic Inflammation". In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
What is the current status of trial NCT05177718?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2022-09-16. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT05177718?
The interventions under investigation include: Natalizumab 300 MG in 15 ML Injection (DRUG).
Who is sponsoring clinical trial NCT05177718?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05177718's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI